Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase

15 Apr 1999

Abstract excerpt

Oxamflatin [(2E)-5-[3-[(phenylsufonyl) aminol phenyl]-pent-2-en-4-ynohydroxamic acid] induces transcriptional activation of junD and morphological reversion in various NIH3T3-derived transformed cell lines. We found that oxamflatin showed in vitro antiproliferative activity against various mouse and human tumor cell lines with drastic changes in the cell morphology and in vivo antitumor activity against B16...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Histone Deacetylase Inhibitors Research
Share to Retinoids in leukemia and cellular processes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 10229197
DOI: 10.1038/sj.onc.1202564

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylasePMID 10229197Read ↗

Oxamflatin: a novel compound which reverses malignant phenotype to normal one via induction of JunD.Semantic proximity Read ↗

NOXA Accentuates Apoptosis Induction by a Novel Histone Deacetylase InhibitorSemantic proximity Read ↗

Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast CancerSemantic proximity Read ↗

Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.Semantic proximity Read ↗

Clinical potential of histone deacetylase inhibitors as stand alone therapeutics and in combination with other chemotherapeutics or radiotherapy for cancer.Semantic proximity Read ↗

[Histone deacetylase inhibitors: highlight on epigenetic regulation].Semantic proximity Read ↗

The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells.Semantic proximity Read ↗

Discovery of Novel Class of Histone Deacetylase Inhibitors as Anticancer AgentsSemantic proximity Read ↗

Histone Deacetylase Inhibitors in Cancer TherapySemantic proximity Read ↗

Histone Deacetylase Inhibitors: Development of Suberoylanilide Hydroxamic Acid (SAHA) for the Treatment of CancersSemantic proximity Read ↗

A Novel Histone Deacetylase Inhibitor Exhibits Antitumor Activity via Apoptosis Induction, F-Actin Disruption and Gene Acetylation in Lung CancerSemantic proximity Read ↗

Novel hydroxamic acid derivative induces apoptosis and constrains autophagy in leukemic cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.